Oral administration of valganciclovir reduces clinical signs experimentally infected with the equid herpesvirus-1

HIGHLIGHTS

• who: EHV- et al. from the 450, Normandie University, UNICAEN, Saint-Contest, France have published the Article: Oral Administration of Valganciclovir Reduces Clinical Signs Experimentally Infected with the Equid Herpesvirus-1, in the Journal: Pathogens 2022, 539 of 24/03/2022
• what: The study aimed to measure the therapeutic efficacy of 2 weeks of VGCV treatment orally administrated immediately after experimental EHV-1 infection (FR- 56628; EHV-1 ORF30 C2254 variant). In the present study, all infected ponies developed respiratory signs two days post infection.
• future: Studies should be carried out to optimise . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.